Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial

REFERENCES

1. 1.↵
   2. Ellingson BM,
   3. Bendszus M,
   4. Boxerman J, et al

   ; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 2015;17:1188–98 doi:10.1093/neuonc/nov095 pmid:26250565

   CrossRefPubMed
2. 2.↵
   2. Eisenhauer EA,
   3. Therasse P,
   4. Bogaerts J, et al

   . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47 doi:10.1016/j.ejca.2008.10.026 pmid:19097774

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Henson JW,
   3. Ulmer S,
   4. Harris GJ

   . Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008;29:419–24 doi:10.3174/ajnr.A0963 pmid:18272557

   Abstract/FREE Full Text
4. 4.↵
   2. Kubben PL,
   3. Postma AA,
   4. Kessels AG, et al

   . Intraobserver and interobserver agreement in volumetric assessment of glioblastoma mulitforme resection. Neurosurgery 2010;67:1329–34 doi:10.1227/NEU.0b013e3181efbb08 pmid:20871451

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Hurwitz H,
   3. Fehrenbacher L,
   4. Novotny W, et al

   . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastic colorectal cancer. N Engl J Med 2004;350:2335–42 doi:10.1056/NEJMoa032691 pmid:15175435

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Norden AD,
   3. Young GS,
   4. Setayesh K, et al

   . Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779–87 doi:10.1212/01.wnl.0000304121.57857.38 pmid:18316689

   Abstract/FREE Full Text
7. 7.↵
   2. Provenzale JM,
   3. Ison C,
   4. Delong D

   . Bidimensional measurements in brain tumors: assessment of interobserver variability. AJR Am J Roentgenol 2009;193:W515–22 doi:10.2214/AJR.09.2615 pmid:19933626

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Ellingson BM,
   3. Kim HJ,
   4. Woodworth DC, et al

   . Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology 2014;271:200–10 doi:10.1148/radiol.13131305 pmid:24475840

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Jensen TR,
   3. Schmainda KM

   . Computer-aided detection of brain tumor invasion using multiparametric MRI. J Magn Reson Imaging 2009;30:481–89 doi:10.1002/jmri.21878 pmid:19711398

   CrossRefPubMed
10. 10.↵
    2. Bedekar D,
    3. Jensen T,
    4. Rand S, et al

    . Delta T1 method: an automatic post-contrast RO1 selection technique for brain tumors. In: Proceedings of the Annual Meeting of the International Society for Magnetic Resonance in Medicine, Stockholm, Sweden. May 1–7, 2010
11. 11.↵
    2. Boxerman JL,
    3. Zhang Z,
    4. Safriel Y, et al

    . Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. Neuro Oncol 2013;15:945–54 doi:10.1093/neuonc/not049 pmid:23788270

    CrossRefPubMed
12. 12.↵
    2. Schmainda KM,
    3. Zhang Z,
    4. Prah M, et al

    . Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol 2015;17:1148–56 doi:10.1093/neuonc/nou364 pmid:25646027

    CrossRefPubMed
13. 13.↵
    2. Ellingson BM,
    3. Kim E,
    4. Woodworth DC, et al

    . Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. Int J Oncol 2015;46:1883–92 doi:10.3892/ijo.2015.2891 pmid:25672376

    CrossRefPubMed
14. 14.↵
    2. Ratai EM,
    3. Zhang Z,
    4. Snyder BS, et al

    . Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. Neuro Oncol 2013;15:936–44 doi:10.1093/neuonc/not044 pmid:23645534

    CrossRefPubMed
15. 15.↵
    2. Nyúl LG,
    3. Udupa JK

    . On standardizing the MR image intensity scale. Magn Reson Med 1999;42:1072–81 doi:10.1002/(SICI)1522-2594(199912)42:61072::AID-MRM11>3.0.CO;2-M pmid:10571928

    CrossRefPubMed
16. 16.↵
    2. Nyúl LG,
    3. Udupa JK,
    4. Zhang X

    . New variants of a method of MRI scale standardization. IEEE Trans Med Imaging 2000;19:143–50 doi:10.1109/42.836373 pmid:10784285

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Krippendorff K

    . Agreement and information in the reliability of coding. Communication Methods and Measures 2011;5:93–112 doi:10.1080/19312458.2011.568376

    CrossRef
18. 18.↵
    2. Dempsey MF,
    3. Condon BR,
    4. Hadley DM

    . Measurement of tumor “size” in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am J Neuroradiol 2005;26:770–76 pmid:15814919

    Abstract/FREE Full Text
19. 19.↵
    2. MacDonald DR,
    3. Cascino TL,
    4. Schold SC Jr., et al

    . Response criteria for phase II studies of malignant glioma. J Clin Oncol 1990;8:1277–80 doi:10.1200/JCO.1990.8.7.1277 pmid:2358840

    Abstract
20. 20.↵
    2. Wen PY,
    3. Macdonald DR,
    4. Reardon DA, et al

    . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

    Abstract/FREE Full Text
21. 21.↵
    2. Wen PY,
    3. Norden AD,
    4. Drappatz J, et al

    . Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep 2010;12:68–75 doi:10.1007/s11912-009-0078-3 pmid:20425610

    CrossRefPubMed
22. 22.↵
    2. Provenzale JM,
    3. Ison C,
    4. Delong D

    . Bidimensional measurements in brain tumors: assessment of interobserver variability. AJR Am J Roentgenol 2009;193:W515–22 doi:10.2214/AJR.09.2615 pmid:19933626

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Bedekar D,
    3. Jensen TR,
    4. Schmainda KM

    . Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons. Magn Reson Med 2010;64:907–13 doi:10.1002/mrm.22445 pmid:20806381

    CrossRefPubMed
24. 24.↵
    2. Prah MA,
    3. Stufflebeam SM,
    4. Paulson ES, et al

    . Repeatability of standardized and normalized relative CBV in patients with newly diagnosed glioblastoma. AJNR Am J Neuroradiol 2015;36:1654–61 doi:10.3174/ajnr.A4374 pmid:26066626

    Abstract/FREE Full Text
25. 25.↵
    2. Ostrom QT,
    3. Gittleman H,
    4. Fulop J, et al

    . CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neuro Oncol 2015;17(Suppl 4):iv1–iv62 doi:10.1093/neuonc/nov189 pmid:26511214

    CrossRefPubMed